Valuation: Mymetics Corp

Market Cap 439K 383K 354K 326K 615K 42.25M 628K 4.23M 1.66M 20.69M 1.65M 1.61M 71.24M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.03M 58.16M 53.61M 101M 6.95B 103M 695M 273M 3.4B 271M 265M 11.71B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -3.64%-2.62%+40.54%+184.05% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2021 2022
Net sales 430K 376K 347K 320K 602K 41.41M 616K 4.14M 1.63M 20.28M 1.61M 1.58M 69.82M 1.03M 898K 829K 764K 1.44M 99M 1.47M 9.91M 3.9M 48.49M 3.86M 3.78M 167M
Net income -4.73M -4.13M -3.81M -3.52M -6.63M -456M -6.77M -45.59M -17.93M -223M -17.76M -17.37M -768M -4.8M -4.2M -3.87M -3.57M -6.73M -463M -6.88M -46.31M -18.22M -227M -18.05M -17.65M -780M
Net Debt 67.1M 58.64M 54.11M 49.88M 94.01M 6.46B 96.09M 647M 254M 3.16B 252M 246M 10.89B 71.68M 62.64M 57.81M 53.28M 100M 6.9B 103M 691M 272M 3.38B 269M 263M 11.64B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-